A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma

被引：1
|
作者：
Luscan, Gerald [1 ]
Paccagnella, Luisa [2 ]
Patel, Krish [3 ]
机构：
[1] Pfizer Int Org, Global Prod Dev, Paris, France
[2] Pfizer Inc, Groton, CT 06340 USA
[3] Swedish Canc Inst, Seattle, WA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182275
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Hoyle, Margaret
    Paccagnella, Luisa
    BLOOD, 2023, 142
  • [2] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ghosh, Nilanjan
    Munoz, Javier
    Morgan, David S.
    Dang, Nam H.
    Knapp, Mark
    Delioukina, Maria
    Kingsley, Edwin C.
    Anh Tran
    Ping, Jerry
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Ruan, Jia
    BLOOD, 2016, 128 (22)
  • [3] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [4] An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
    Morschhauser, Franck
    Salles, Gilles
    Le Gouill, Steven
    Tilly, Herve
    Thieblemont, Catherine
    Bouabdallah, Krimo
    Fabiani, Bettina
    Menard, Cedric
    Tarte, Karin
    Cartron, Guillaume
    Houot, Roch
    BLOOD, 2018, 132 (14) : 1486 - 1494
  • [5] A Phase 1/1b Open-Label, Multicenter, Two- Part Study of SETD2 Inhibitor EZM0414 in Patients with Relapsed/Refractory Multiple Myeloma or Diffuse Large B-Cell Lymphoma
    Richardson, Paul G.
    Niesvizky, Ruben
    Yang, Jay
    Yadav, Neelu
    Hsu, Helen
    Flowers, Christopher R.
    BLOOD, 2021, 138
  • [6] Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data
    Ferhanoglu, Burhan
    Gulbas, Zafer
    Uzay, Ant
    Ozcan, Muhit
    Ozkalemkas, Fahir
    Dal, Mehmet Sinan
    Kalyon, Hakan
    Akay, Olga Meltem
    Deveci, Burak
    Bekoz, Huseyin
    Sevindik, Omur Gokmen
    Toptas, Tayfur
    Yilmaz, Asu Fergun
    Koyun, Derya
    Alkis, Nihan
    Atesoglu, Elif Birtas
    BLOOD, 2022, 140 : 6704 - 6705
  • [7] Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
    Cheah, Chan Yoon
    Belada, David
    Fanale, Michelle A.
    Janikova, Andrea
    Czucman, Myron S.
    Flinn, Ian W.
    Kapp, Amy V.
    Ashkenazi, Avi
    Kelley, Sean
    Bray, Gordon L.
    Holden, Scott
    Seymour, John F.
    LANCET HAEMATOLOGY, 2015, 2 (04): : E166 - E174
  • [8] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
    Palomba, M. Lia
    Till, Brian G.
    Park, Steven I.
    Morschhauser, Franck
    Cartron, Guillaume
    Marks, Reinhard
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Popplewell, Leslie L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
  • [9] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [10] A Phase 2, Open-Label, Multicenter Study of Tazemetostat in Combination with Rituximab for the Treatment of Relapsed or Refractory Follicular Lymphoma
    Patel, Krish
    Bailey, Neil
    Pagel, John M.
    BLOOD, 2020, 136
12345